BioArctic AB has announced that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. The patent comes into force on 27 January 2021 and expires in 2030.
According to a company press release, the newly granted patent focuses on novel antibodies which target pE3-Ab, a specific truncated form of amyloid beta.
BioArctic states the granted patent underlines its commitment in the brain diseases field in general and in Alzheimer’s disease research specifically. The company claims that by focusing on additional forms of amyloid beta species in the disease cascade, it broadens the company’s scope to affect the disease pathology in addition to lecanemab (BAN2401) – the company’s primary Alzheimer’s disease drug candidate currently in phase III – widening the field for future treatment possibilities.
Gunilla Osswald (Stockholm, Sweden), the chief executive officer of BioArctic, commented: “We are pleased that our patent has been granted for these novel antibodies. More than 30 million people around the world live with Alzheimer’s disease today and there is a large medical need. We continue to work tirelessly to develop and give these patients access to the treatments they deserve.”